tbuckley/cabot-search huggingface dataset:
Korean red ginseng to improve cancer-related fatigue in colorectal cancer patients with FOLFOX chemotherapy: A randomized, double-blind, placebo-controlled, parallel, multicenter trial, NCT02039635.
Authors: Yeul Hong Kim, Yoojoo Lim, Jae Yong Cho, Ik-Joo Chung, Jong Gwang Kim, Kyung Hee Lee, Keon Uk Park, Sun Kyung Baek, Sang Cheul Oh, Myung Ah Lee, Doyeun Oh, Byoungyong Shim, Jin Won Kim, Joong Bae Ahn, Dongbok Shin
Journal: Journal of Clinical Oncology (2017)

10008 Background: Cancer-related fatigue(CRF) is a common and severe symptom in patients with cancer. The purpose of this study is to evaluate the anti-fatigue effect of Korean Red Ginseng(Steamed Panax ginseng C.A. Meyer) on patients with colorectal cancer. Methods: 438 colorectal cancer patients in treatment with mFOLFOX-6 regimen were randomly assigned to either the Korean Red Ginseng[KRG](n = 219) or placebo(n = 219) group and received 2,000 mg/day test substances for 16 weeks. The primary endpoint was the Area Under Curve(AUC) of Brief Fatigue Inventory(BFI) over 16 weeks. The AUC and change from the baseline were calculated. The frequency and types of adverse events were determined by the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 4.0. Results: 438 colorectal cancer patients were enrolled from 15 institutions. Changes from the baseline in the global BFI were 78.54(Standard deviation [SD] = 16.91) in KRG group vs. 75.89(SD = 16.85) in placebo group at 16 weeks(P = 0.0363). Changes from the baseline in the Usual Fatigue were 76.15 (SD = 17.08) in KRG group vs. 73.08(SD = 17.03) in placebo group at 16 weeks(P = 0.0454). Changes from the baseline in the Mood were 80.46(SD = 17.16) in KRG group vs. 77.88(SD = 17.59) in placebo group at 16 weeks(P = 0.0086). Changes from the baseline in the Relations with Others were 82.09(SD = 17.49) in KRG group vs. 78.67(SD = 17.90) in placebo group at 16 weeks(P = 0.0080). Changes from the baseline in the Walking ability were 82.70(SD = 17.28) in KRG group vs. 80.77(SD = 16.47) in placebo group at 16 weeks(P = 0.0090). Changes from the baseline in the Enjoyment of life were 79.53(SD = 19.53) in KRG group vs. 77.51(SD = 18.02) in placebo group at 16 weeks(P = 0.0150). Toxicities per self-report and CTCAE grading did not differ statistically significantly between the groups. Conclusions: The data supports benefits of consuming 2,000 mg KRG water extract powder daily on CRF over 16-week period. There were no discernible toxicities associated with the treatment. More studies on mechanisms of KRG to guide its role in CRF improvement are needed. Clinical trial information: NCT02039635.
Effects of Oral vs Transdermal Estrogen Therapy on Sexual Function in Early Postmenopause
Authors: Hugh S. Taylor, Aya Tal, Lubna Pal, Fangyong Li, Dennis M. Black, Eliot A. Brinton, Matthew J. Budoff, Marcelle I. Cedars, Wei Du, Howard N. Hodis, Rogerio A. Lobo, JoAnn E. Manson, George R. Merriam, Virginia M. Miller, Frederick Naftolin, Genevieve Neal-Perry, Nanette F. Santoro, Sherman M. Harman
Journal: JAMA Internal Medicine (2017)

Sexual dysfunction, an important determinant of women's health and quality of life, is commonly associated with declining estrogen levels around the menopausal transition.To determine the effects of oral or transdermal estrogen therapy vs placebo on sexual function in postmenopausal women.Ancillary study of the Kronos Early Estrogen Prevention Study (KEEPS), a 4-year prospective, randomized, double-blinded, placebo-controlled trial of menopausal hormone therapy in healthy, recently menopausal women. Of 727 KEEPS enrollees, 670 agreed to participate in this multicenter ancillary study. Women were 42 to 58 years old, within 36 months from last menstrual period. Data were collected from July 2005 through June 2008 and analyzed from July 2010 through June 2017.Women were randomized to either 0.45 mg/d oral conjugated equine estrogens (o-CEE), 50 µg/d transdermal 17β-estradiol (t-E2), or placebo. Participants also received 200 mg oral micronized progesterone (if randomized to o-CEE or t-E2) or placebo (if randomized to placebo estrogens) for 12 days each month.Aspects of sexual function and experience (desire, arousal, lubrication, orgasm, satisfaction, and pain) were assessed using the Female Sexual Function Inventory (FSFI; range, 0-36 points; higher scores indicate better sexual function). Low sexual function (LSF) was defined as an FSFI overall score of less than 26.55. Distress related to low FSFI score (required for the diagnosis of sexual dysfunction) was not evaluated.The 670 participants had a mean (SD) age of 52.7 (2.6) years. The t-E2 treatment was associated with a significant yet moderate improvement in the FSFI overall score across all time points compared with placebo (average efficacy, 2.6; 95% CI, 1.11-4.10; adjusted P = .002). With o-CEE treatment, there was no significant difference in FSFI overall score compared with placebo (mean efficacy, 1.4; 95% CI, -0.1 to 2.8; adjusted P = .13). There was no difference in FSFI overall score between the t-E2 and o-CEE groups on average across 48 months (adjusted P = .22). In the individual domains of sexual function, t-E2 treatment was associated with a significant increase in mean lubrication (0.61; 95% CI, 0.25-0.97; P = .001) and decreased pain (0.67; 95% CI, 0.25-1.09; P = .002) compared with placebo. Overall, the proportion of women with LSF was significantly lower after t-E2 treatment compared with placebo (67%; 95% CI, 55%-77% vs 76%; 95% CI, 67%-83%; P = .04). For o-CEE there was no significant reduction in the odds of LSF.Treatment with t-E2 modestly improved sexual function in early postmenopausal women, but whether it relieved symptoms of distress is not known.clinicaltrials.gov Identifier: NCT00154180.
Well-Differentiated Thyroid Cancer Neovasculature Expresses Prostate-Specific Membrane Antigen—a Possible Novel Therapeutic Target
Authors: Maureen Moore, Suraj Panjwani, Rashmi Mathew, Michael Crowley, Yi-Fang Liu, Anna Aronova, Brendan Finnerty, Rasa Zarnegar, Thomas J. Fahey, Theresa Scognamiglio
Journal: Endocrine Pathology (2017)
CGジヌクレオチドの自由導入遺伝子配列は高レベル,プラスミドバックボーン設計の独立した肺の長期発現をもたらす【Powered by NICT】
Authors: P Bazzani Reto, A Pringle Ian, M Connolly Mary, A Davies Lee, G Sumner-Jones Stephanie, Schleef Martin, C Hyde Stephen, R Gill Deborah
Journal: Biomaterials (2016)
Progressive Annular Plaques in a Toddler
Authors: Kimberly Hyde, Austin Cope, Jennie T. Clarke
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Randomized Study of Pegasparagase (SS-PEG) and Calaspargase Pegol (SC-PEG) in Pediatric Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Results of DFCI ALL Consortium Protocol 11-001
Authors: Lewis B. Silverman, Traci M. Blonquist, Sarah K. Hunt, Samantha Kay-Green, Uma H. Athale, Luis A. Clavell, Peter D. Cole, Kara M. Kelly, Caroline Laverdiere, Jean-Marie Leclerc, Bruno Michon, Marshall A. Schorin, Maria Luisa Sulis, Jennifer J.G. Welch, Jeffrey G. Supko, Xiaoyong He, Sarah Hilderbrand, Andrew E. Place, Lynda M. Vrooman, Marian H. Harris, Kristen E. Stevenson, Donna S. Neuberg, Stephen E. Sallan
Journal: Blood (2016)
Charting Our Future Together
Authors: Gary H. Gibbons
Journal: Circulation (2017)

director of the National Heart, Lung, and Blood Institute (NHLBI), it is my privilege to be a public servant and an accountable steward of the nation's investment in heart, lung, blood, and sleep research.The NHLBI strives to advance science that enhances human health through several enduring principles that have sustained the Institute's legacy of excellence: value investigator-initiated fundamental discovery science; maintain a balanced portfolio across basic, translational, clinical, population, and implementation science; train a diverse new generation of scientists; support implementation science that empowers patients and partners to improve the nation's health; and innovate an evidence-based elimination of health inequities.The pursuit of the NHLBI mission involves the collective effort of a diverse community of partners including patients, researchers, policymakers, care providers, professional organizations, and the private sector.Over the past 2 years, we engaged our partners in a process of unprecedented scope to create the NHLBI Strategic Vision, a framework of research priorities to guide the activities and initiatives that NHLBI will catalyze over the next decade. 1 The Strategic Visioning process revealed an NHLBI community poised to take bold steps forward toward the prevention and preemption of cardiovascular disease.The Strategic Vision charts a future that exploits emerging disciplines and new tools and technologies in computation, imaging, and high-throughput omic analytics to further our understanding of normal biology, pathobiology, individual and population differences, precision medicine, data science, novel therapeutics and diagnostics, and workforce development.Below, I highlight 2 areas in the Strategic Vision that hold great promise for cardiovascular research and health: precision medicine and the interface with data science.
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus Infection
Authors: Nicholas S. Heaton, Natasha Moshkina, Romain Fenouil, Thomas J. Gardner, Sebastian Aguirre, Priya S. Shah, Nan Zhao, Lara Manganaro, Judd F. Hultquist, Justine Noel, David Sachs, Jennifer Hamilton, Paul E. Leon, Amit Chawdury, Shashank Tripathi, Camilla Melegari, Laura Campisi, Rong Hai, Giorgi Metreveli, Andrea V. Gamarnik, Adolfo García-Sastre, Benjamin Greenbaum, Viviana Simon, Ana Fernandez-Sesma, Nevan J. Krogan, Lubbertus C.F. Mulder, Harm van Bakel, Domenico Tortorella, Jack Taunton, Peter Palese, Ivan Marazzi
Journal: Immunity (2016)
Comment on Young-Hyman et al. Psychosocial Care for People With Diabetes: A Position Statement of the American Diabetes Association. Diabetes Care 2016;39:2126–2140
Authors: Frank J. Snoek, Norbert Hermanns, Maartje de Wit, Jörg Huber, Jackie Sturt, François Pouwer, Cathy E. Lloyd, Ingrid Willaing, Arie Nouwen
Journal: Diabetes Care (2018)

Thanks to Drs. Kalra, Balhara, Mezuk, Pouwer, and Campbell and Ms. Macdonald for their careful consideration (1–3) of the first American Diabetes Association (ADA) psychosocial guidelines Position Statement (4). Kalra and Balhara (1) note the overlaps and differences in the content of the ADA and Indian position statements, with particular emphasis on the cultural appropriateness and specificity of recommendations. Mezuk and Pouwer (2) question the need for routine screening for depression in persons with impaired glucose metabolism and undiagnosed diabetes based on meta-analytic results (5) and note the need to address disparities in diabetes burden and quality of care. They further suggest the need for action steps for practitioners once psychosocial issues are identified that impact health outcomes. These concerns are echoed by Macdonald and Campbell (3) when identifying that emphasis on compliance can cause blame to be placed on patients through misguided interpretation of the patient-centered paradigm. They suggest that this might be avoided through “long-term” care, by which they appear to mean the relationship formed through long-term follow-through by a consistent care provider.

These authors identify social issues that are not explicitly addressed in the ADA Position Statement: barriers to getting married, gender-based issues, geographically based management challenges, culturally specific intervention strategies for increasing well-being, disparities in burden and quality of care for …
Abstract 132: CD13 and ROR2 Mediated Isoloation of hESC Derived Cardiac Mesoderm
Authors: Bevin Brady, Rhys J Skelton, David A Elliott, Irving L Weissman, Reza Ardehali
Journal: Circulation Research (2013)

The human heart has a limited regenerative capacity and there is an unmet demand for improved therapies for myocardial disease. Human embryonic stem cell (hESC) derived cardiomyocytes have potential to facilitate the development of both cell-based and pharmaceutical treatments. To date many studies have focused on the efficient generation of cardiomyocytes from hESCs. However, its clinical use has been limited by technical challenges, including the inability to isolate a pure population of cardiovascular progenitors capable of robust engraftment and regeneration. To this end, we have attempted to identify surface markers that facilitate isolation of cardiac mesoderm and cardiovascular progenitors from differentiating hESCs. Lineage-specific reporter hESC lines (MIXL1-GFP and NKX2.5-GFP) were utilized to test prospective isolation of early cardiac progenitors using two novel cell surface markers, CD13 and ROR2. A distinct population of cells co-expressing CD13 and ROR2 was isolated after 3 days of hESC differentiation which exhibited a transcriptional profile similar to primitive streak/mesoderm cells. Gene expression analysis and immunostaining confirmed the enrichment of mesodermal cells and near complete removal of endodermal, ectodermal and undifferentiated cells. To quantify the extent of cardiovascular progenitors generated from CD13/ROR2 expressing cells, an NKX2.5-GFP reporter hESC line was used and the double positive cells were sorted after 3 days and maintained in culture for 14 days. The majority of these cells showed enrichment for cardiovascular cells based on gene and protein expression, phenotype, and transplantation studies. By enabling retrieval of early mesoderm precursors from heterogeneous differentiated hESC populations, we anticipate CD13 and ROR2 should have utility in enriching for subsequent cardiac potential_the necessary first developmental step towards creating purified cardiomyocytes from hESC.
Abstract 322: Reversal of Intramuscular Lipotoxicity is Mediated by a Novel p62-lipophagy Pathway
Authors: Truong N Lam, Romain Harmancey, Hernan Vasquez, Nina Patel, Blaine Gilbert, Heinrich Taegtmeyer
Journal: Circulation Research (2015)

Background and Hypothesis: In the mammalian heart, autophagy is considered an adaptive mechanism promoting the removal of protein aggregates or damaged cell organelles. A common feature of non-ischemic heart failure is lipid accumulation. We hypothesize that autophagy is impaired in the muscle in chronic lipid overload. Therefore, we investigated whether activation of autophagy protects myocytes from lipotoxicity. Methods: We incubated rat L6 myocytes over a period of 6 days with or without long chain fatty acids (equimolar mixture of oleate and palmitate, 1.0mM). At day 6, an autophagic inhibitor (bafilomycin A1, 200 nM), or an autophagic activator (rapamycin, 1 μM), or both, were added for 48 hours. Following the pharmacologic treatments, glucose uptake was measured using [3H] 2-Deoxy-D-glucose, and insulin sensitivity was assessed. Intracellular triglyceride (TG) accumulation was assessed by Oil Red O staining and immunofluorescence and was quantified enzymatically. Protein markers of autophagic flux (LC3 and p62) and cell death (Caspase 3 cleavage) were measured by immunoblotting. Results: Inhibition of autophagy using bafilomycin increased TG accumulation and also increased fatty acid-mediated cell death. Conversely, activation of autophagy using rapamycin reduced both intracellular lipid accumulation and cell death. Unexpectedly, treatment with both rapamycin and bafilomycin resulted in a decrease in lipid accumulation. Immunoblotting indicated p62 degradation (autophagic flux), while immunofluorescence revealed the colocalization of p62 with lipid droplets in these cells. These findings indicate the potential association of p62 with lipid droplet turnover, which is a novel pathway for the breakdown of lipid droplets in muscle cells. In the same cells, rapamycin treatment increased glucose uptake, in response to insulin (100mM). Conclusions: Autophagy promotes the clearance of lipids from myocytes, improves insulin sensitivity, and switches to an alternative p62 mediated pathway of lipophagy in the context of chronic lipid overload. Moreover, lipophagy promotes metabolic adaptation and myocyte survival.
心臓ホーミング多孔質シリコンナノ粒子のin vitroおよびin vivo評価【Powered by NICT】
Authors: P A Ferreira Monica, Ranjan Sanjeev, M R Correia Alexandra, M Maekilae Ermei, M Kinnunen Sini, Zhang Hongbo, Shahbazi Mohammad-Ali, V Almeida Patrick, J Salonen Jarno, J Ruskoaho Heikki, J Airaksinen Anu, T Hirvonen Jouni, A Santos Helder
Journal: Biomaterials (2016)
PTU-008 Rigid sigmoidoscopy: a dying skill in gastroenterology?
Authors: E Selvaraj, D Gorard
Journal: Gut (2017)

Introduction  Rigid sigmoidoscopy is a cost-effective tool to rapidly investigate lower gastrointestinal symptoms in outpatient clinics. Since rigid sigmoidoscopy rarely inspects mucosa proximal to the rectum, it is diagnostically inferior to flexible sigmoidoscopy. However it allows early diagnosis/treatment of ulcerative colitis, and in excluding colitis in young patients with diarrhoeal symptoms, it obviates the need for (expensive) flexible endoscopy. With increased accessibility to flexible sigmoidoscopy, we hypothesised that rigid sigmoidoscopy use has declined. Unlike the general surgery curriculum, there is no formal requirement in the gastroenterology curriculum or structured training to achieve competence in this procedure.  Method  This study aimed to assess the level of experience and training in rigid sigmoidoscopy received by current UK gastroenterology trainees. An online survey was disseminated via the British Society of Gastroenterology Trainee Chair to 850 gastroenterology trainees throughout the UK. The survey was open for a 4 week period.  Results  164 trainees responded (19.3% response rate). Respondents were fairly evenly distributed from different stages of training: LAS 1%, ST3 14%, ST4 20%, ST5 19%, ST6 15%, ST7 14% and Out-of-Programme 17%. 57% respondents had never performed a rigid sigmoidoscopy, 23% 20 procedures. Of those trainees performing rigid sigmoidoscopy, 12% had been supervised in performing >5 procedures, 70% in performing 1–4 procedures, and 18% stated they had never received supervision.  Of trainees performing rigid sigmoidoscopy, 90% use it only in clinic, while 10% were able to perform sigmoidoscopy on inpatients; only 4.5% obtain written consent. 99% of trainees had not undertaken a formal DOPS assessment, 76% felt that training in rigid sigmoidoscopy was non-existent, 15% insufficient and 8% just adequate. 55% felt that rigid sigmoidoscopy would be a useful tool in clinic and 51% would like it to be incorporated into the curriculum. For future trainees, 24% felt that no formal training is required but 57% felt that formative and summative DOPS should be undertaken. The average waiting time for flexible sigmoidoscopy was 2–4 weeks in 51% of responses and >4 weeks in 30% of responses. 76% trainees said that their current supervising consultant did not perform rigid sigmoidoscopies.  Conclusion  Rigid sigmoidoscopy is not a widely used or taught procedural skill among current gastroenterology trainees. Trainees agree that there needs to be a more structured approach to teaching and training in rigid sigmoidoscopy with formal assessments of competency. Unless the expectation is that future UK consultant gastroenterologists will not use rigid sigmoidoscopy, the British Society of Gastroenterology needs to lead in ensuring the technique is taught to trainees.  Disclosure of Interest  None Declared
自然加工を模倣することにより官能化絹整形外科デバイスのための再生絹材料【Powered by NICT】
Authors: Li Chunmei, Hotz Blake, Ling Shengjie, Guo Jin, S Haas Dylan, Marelli Benedetto, Omenetto Fiorenzo, J Lin Samuel, L Kaplan David
Journal: Biomaterials (2016)
‘Altmetrics’! Can you afford to ignore it?
Authors: Steffan Arthur Griffin, Christopher W Oliver, Andrew Murray
Journal: British Journal of Sports Medicine (2017)

Number of citations, number of views, Altmetric. To be a relevant and respected researcher, and to succeed in the current ‘publish or perish’ climate, it is important to publish, and to communicate and disseminate research widely to increase its likelihood of influencing clinical and research practice. With over two million scientific articles being produced each year1 (and rising), how can you ensure your contribution is impactful?

The number of citations in other published articles and ‘number of views’ has long been used as a guide to assess the impact of a paper.2 This may not be an effective ‘real-time’ measure as some impactful papers take years to generate citations. A journal’s impact factor (IF) has also been viewed as a measure of respectability and an indirect proxy of an article’s impact. However, questions arise regarding such ‘journal-level’ metrics when it comes …